Elobopa ELTROBOPAG 25MG 28 TABS Approval No. 10 L 0731/17 Validity Date 06-8-2027

Eltrombopag (trade name: Elobopa) is a drug used to treat thrombocytopenia, especially for patients with certain blood disorders such as immune thrombocytopenia (ITP) and myelodysplastic syndrome (MDS). Here is some basic information about Eltrombopag:

1. Drug classification :

• Eltrombopag is a thrombopoietin receptor agonist (TPO-R agonist) that promotes platelet production by stimulating the thrombopoietin receptor.

2. Indications :

• Immune thrombocytopenia (ITP) : For the treatment of adults and children (1 year and older) with chronic ITP when conventional treatments have failed.
• Thrombocytopenia associated with chronic liver disease : For the treatment of thrombocytopenia in patients with cirrhosis.
• Myelodysplastic syndrome (MDS) : Used to treat patients with MDS to increase platelet counts.
• Severe aplastic anemia (SAA) : Used in combination with immunosuppressive therapy to improve platelet counts in patients with SAA.

3. Usage and dosage :

• Adults and Children : Eltrombopag is usually administered orally, with the recommended dose being once daily, adjusted based on the individual condition.
  • For immune thrombocytopenia (ITP), the recommended initial dose is 50 mg/day (adults), and the dose for children is adjusted according to weight.
  • For chronic liver disease-associated thrombocytopenia and MDS, the recommended initial dose is 25 mg/day.
• The dosage and duration of the drug should be individually adjusted by the physician based on the patient's condition and platelet response.

4. Notes :

• Liver function : Eltrombopag may affect liver function, especially in patients with cirrhosis. Liver function tests should be performed regularly during use.
• Thrombotic risk : There is a possibility of increased risk of thrombosis, and patients should pay special attention to symptoms such as deep vein thrombosis or pulmonary embolism.
• Duration of medication : During treatment, regularly monitor the platelet count to ensure therapeutic effectiveness.
• Drug interactions : Eltrombopag may interact with certain drugs (such as antacids, calcium channel blockers, etc.), requiring adjustment of medication or interval time during use.

5. Side effects :

• Possible side effects include: nausea, vomiting, headache, diarrhea, abnormal liver function, bone marrow suppression, etc.
• Careful monitoring is required for possible liver dysfunction and thrombosis.

6. Contraindications :

• Eltrombopag is contraindicated in patients with hypersensitivity to eltrombopag or its components.
• Use with caution in patients with severe liver disease or hepatic impairment.

7. Pregnancy and lactation :

• Pregnancy : The safety of eltrombopag for the fetus is unknown. Pregnant women should avoid using eltrombopag unless there is a clear medical need.
• Lactation : Since eltrombopag may be secreted into breast milk, it should be used with caution in breastfeeding patients and it is recommended to suspend breastfeeding during treatment.

8. Storage :

• Eltrombopag should be stored at room temperature away from moisture and heat.

Please note : The above is only general information and does not cover all usage details. Before using Eltrombopag, you should read the drug instructions carefully and consult a doctor or pharmacist to ensure safe use.